DataMeds AI ATM common stock offering up to $10,003,649
DataMeds AI, Inc. entered an ATM sales agreement with Dawson James Securities, Inc. to sell common stock from time to time with an aggregate offering price of up to $10,003,649. The company will pay 3.0% of aggregate gross proceeds for sales made through Dawson James as agent and intends to use net proceeds for debt repayment, working capital and other general corporate purposes. The filing's $0.74-per-share illustration assumes up to 13,518,445 shares sold and up to 19,243,302 shares outstanding afterward, with...
Key takeaways
Offering size and float cap: DataMeds may sell common stock with an aggregate offering price of up to $10,003,649 under an at-the-market offering; while public float remains below $75.0 million, the company is subject to a one-third-of-public-float limit over a 12-month period.
Sales agent: Dawson James Securities, Inc. may act as sales agent or principal, and the company may deliver placement notices specifying the maximum number of shares to sell and a minimum sale price.
Compensation: Dawson James is entitled to a 3.0% cash commission on aggregate gross proceeds from shares sold as agent, and the company will reimburse specified Sales Agent expenses.
Use of proceeds: Net proceeds, if any, are intended for debt repayment, working capital and other general corporate purposes, with temporary investment in capital-preservation instruments pending use.
Illustrative share count: At $0.74 per share, the filing assumes up to 13,518,445 shares sold and up to 19,243,302 shares outstanding afterward, compared with 5,724,857 shares outstanding before the offering.
Net tangible book value: At September 30, 2026, historical net tangible book value was $(28.9) million, or $(6.10) per share; after the full assumed offering, pro forma as-adjusted net tangible book value would be $(19.8) million, or $(1.03) per share, with $1.77 of per-share dilution.
Funding uncertainty: No minimum offering amount is required, the actual total offering amount and net proceeds are not determinable, and there is no assurance that any shares will be sold or that the full capacity will be used.
Key metrics
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open SEC filingFollow MEDS in real time
Get material earnings, filing, IR, and earnings-call alerts by email.